Your office may also opt out of the program on behalf of your patients. Patients can opt out of the TYSABRI Ongoing Support Program at any time and still continue to take advantage of resources offered through Biogen Support Services. As their 1-year anniversary on TYSABRI approaches, a Biogen Nurse Educator will check in with patients once again and continue to follow up about every 6 months thereafter.After the first-dose follow-up call, a Nurse Educator will contact patients to ask about their experience and remind them about the re-authorization process.Patients will receive a welcome call and a first-dose follow-up call from a Biogen Case Manager.Once patients are registered in the TOUCH ® Prescribing Program, they are automatically enrolled to participate in the TYSABRI Ongoing Support Program. Provide the Medication Guide to your patients and encourage discussion.The optional TYSABRI Ongoing Support Program provides patients with periodic check-ins from Biogen Case Managers (Support Coordinators) and Nurse Educators to assess patients’ progress on therapy and to answer any questions they may have about their treatment with TYSABRI. Please read the full Prescribing Information and Medication Guide for TREMFYA ®. The overall safety profile observed in patients with psoriatic arthritis is generally consistent with the safety profile in patients with plaque psoriasis, with the addition of bronchitis and neutrophil count decreased. Most common (≥1%) adverse reactions associated with TREMFYA ® include upper respiratory infections, headache, injection site reactions, arthralgia, bronchitis, diarrhea, gastroenteritis, tinea infections, and herpes simplex infections. Avoid use of live vaccines in patients treated with TREMFYA ®. Prior to initiating TREMFYA ®, consider completion of all age-appropriate immunizations according to current immunization guidelines. Do not administer TREMFYA ® to patients with active TB infection. Monitor patients for signs and symptoms of active TB during and after TREMFYA ® treatment. Initiate treatment of latent TB prior to administering TREMFYA ®. Pre-Treatment Evaluation for Tuberculosis (TB)Įvaluate patients for TB infection prior to initiating treatment with TREMFYA ®. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue TREMFYA ® until the infection resolves. Instruct patients receiving TREMFYA ® to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. Treatment with TREMFYA ® should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated.Ĭonsider the risks and benefits of treatment prior to prescribing TREMFYA ® in patients with a chronic infection or a history of recurrent infection. TREMFYA ® may increase the risk of infection. If a serious hypersensitivity reaction occurs, discontinue TREMFYA ® and initiate appropriate therapy. Serious hypersensitivity reactions, including anaphylaxis, have been reported with postmarket use of TREMFYA ®. TREMFYA ® is contraindicated in patients with a history of serious hypersensitivity reaction to guselkumab or to any of the excipients.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |